Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

F. Seymour, John; J. Kipps, Thomas; Eichhorst, Barbara; Hillmen, Peter; D’Rozario, James; Assouline, Sarit; Owen, Carolyn; F. Gerecitano, John; Robak, Tadeusz; de la Serna, Javier; Jaeger, Ulrich; Cartron, Guillaume; Montillo, Marco; Humerickhouse, Rod; A. Punnoose, Elizabeth; Li, Yan; Boyer, Michelle; Humphrey, Kathryn; Mobasher, Mehrdad; P. Kater, Arnon

doi:10.1056/nejmoa1713976

Public

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

Published in New England Journal of Medicine • Mar 21, 2018

Authors:

John F. Seymour

Thomas J. Kipps

Barbara Eichhorst

Abstract

BACKGROUND: Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We evaluated the efficacy of venetoclax in combination with rituximab in patients with relapsed or refractory chronic lymphoc...

Subject

Venetoclax

Rituximab

Bendamustine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!